Immunovant – Talk Bio

Actionable Insights Powered by AI

Immunovant Refines R&D Strategy with New Leadership

3 days ago talkbio0Tagged Changing, Focal, Immunovant, Leadership, Roivant

Immunovant, Roivant, R&D Focus, Leadership Changes, IMVT-1402

Immunovant Shifts Focus to Next-Gen Drug Despite Positive Phase 3 Results for Batoclimab in Myasthenia Gravis

1 month ago talkbio0Tagged Autoimmune Diseases, Batoclimab, FCGRT gene, FcRn, Immunovant, IMVT-1402, Inhibitor, Myasthenia Gravis, Phase 3

Immunovant, batoclimab, myasthenia gravis, Phase 3 success, IMVT-1402, FcRn inhibitor, autoimmune disorders

Immunovant Shifts Focus to Next-Generation FcRn Inhibitor IMVT-1402, Delaying Batoclimab Development ###

11 months ago talkbio0Tagged Autoimmune Diseases, Batoclimab, Biological Factors, FCGRT gene, FcRn, Immunovant, IMVT-1402, Inhibitor, Roivant

Immunovant, IMVT-1402, FcRn inhibitor, Batoclimab, Autoimmune diseases, Vyvgart, Roivant, Biopharmaceuticals